We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Research Breakthroughs in Imaging Biomarker Technology

By Biotechdaily staff writers
Posted on 30 Jul 2008
While currently the largest distributor of positron emission tomography (PET) radiopharmaceuticals in the United States and expanding internationally into countries and regions, such as India, the United Kingdom, Korea, and Australia, Siemens Healthcare (Erlangen, Germany) is also making progress into developing new imaging biomarkers that may be used in the future. More...


Siemens Molecular Imaging Biomarker Research facility, located in Los Angeles, CA, USA, has recently submitted an Investigational New Drug (IND) application for a new imaging agent that will help with imaging hypoxic tumors, which may be resistant to standard treatment involving chemotherapy. This type of imaging biomarker may be valuable in managing the treatment options for cancer patients.

Siemens also recently announced that the U.S. National Cancer Institute (NCI) has filed a cross-reference letter to a Type II Drug Master File that Siemens submitted to the U.S. Food and Drug Administration for its investigational 3'Deoxy-3'[18F] fluorothymidine (F-18 FLT) imaging biomarker. The cross reference allows F-18 FLT to be produced by Siemens/PETNET and used by any principle investigator in an NCI multicenter clinical trial. Moreover, the imaging biomarker will be available to independent investigators if they receive NCI approval. F-18 FLT is produced by Siemens Molecular Imaging Biomarker Research and PETNET Solutions, subsidiaries of Siemens Medical Solutions USA, Inc. The imaging biomarker has been used in studies monitoring the proliferative activity of cancer cells and it is currently being used in phase I clinical trials at several research sites.

Siemens Molecular Imaging (MI) University provides a substantive training resource for Siemens' customers. Designed to be used by the interpreting physician, referring physician, and technologist, MI University demonstrates the benefits of hybrid PET-computed tomography (CT) and single photon emission tomography- (SPECT)-CT systems, including when and how hybrid imaging influences patient management, through access to valuable clinical data and detailed case studies; video lectures; product information; and a tool for information exchange among peers

Siemens Healthcare is one of the world's largest suppliers to the healthcare industry. The company is a medical solutions provider with core competence in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Healthcare is a fully integrated diagnostics company, bringing together imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services.


Related Links:
Siemens Healthcare
Siemens Molecular Imaging

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.